This phase II trial is evaluating how safe and effective a targeted therapy (Mirvetuximab Soravtansine) in people with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
This trial is treating patients with ovarian, peritoneal and fallopian tube cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Commercial Sponsor
ImmunoGen, Inc.
Summary
Eligible participants will receive Mirvetuximab Soravtansine (MIRV), via intravenous infusion, at a dose of 6.0mg/kg adjusted by ideal body weight on Days 1 of every 3-week cycle.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More